Weight loss is an important goal in the management of several chronic conditions, including type 2 diabetes mellitus, and pharmacological therapies that aid weight loss are appealing. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) are novel glucose-lowering therapies that have been shown to induce clinically significant reductions in body weight. However, this weight loss may not be attributed solely to fat mass (FM). Given the importance of skeletal muscle and lean body mass (LBM) on cardio-metabolic health and physical function, we reviewed the available literature reporting the effects of GLP-1RAs and SGLT2is on body composition. Results demonstrate that, in most circumstances, the weight loss associated with both therapies predominantly comprises a reduction in FM, although significant heterogeneity exists between studies. In over half of the studies identified, the proportion of LBM reduction ranged between 20% and 50% of total weight lost, which is consistent with diet-induced weight loss and bariatric surgery. No clear differences existed between GLP-1RAs and SGLT2is. Consequently, the loss of LBM and skeletal muscle associated with weight loss induced by GLP-1RAs and SGLT2is warrants attention. Strategies to preserve skeletal muscle and improve physical function, for example through structured exercise, are of great importance.

Citations

Citations to this article as recorded by  

• Malnutrition in real-world patients hospitalized for heart failure with preserved ejection fraction and its potential impact on generalizability of EMPEROR-Preserved trial
  Shinsuke Takeuchi, Takashi Kohno, Ayumi Goda, Yasuyuki Shiraishi, Mike Saji, Yuji Nagatomo, Toshikazu D. Tanaka, Makoto Takei, Shintaro Nakano, Kyoko Soejima, Shun Kohsaka, Tsutomu Yoshikawa
  International Journal of Cardiology.2023; 370: 263.     CrossRef
• Marked weight loss on liraglutide 3.0 mg: Real‐life experience of a S wiss cohort with obesity
  Sara Santini, Nathalie Vionnet, Jérôme Pasquier, Elena Gonzalez‐Rodriguez, Montserrat Fraga, Nelly Pitteloud, Lucie Favre
  Obesity.2023; 31(1): 74.     CrossRef
• Early type 2 diabetes treatment intensification with glucagon‐like peptide‐1 receptor agonists in primary care: An Australian perspective on guidelines and the global evidence
  Roy Rasalam, Sarah Abdo, Gary Deed, Richard O'Brien, Jane Overland
  Diabetes, Obesity and Metabolism.2023; 25(4): 901.     CrossRef
• The effects of weight‐lowering pharmacotherapies on physical activity, function and fitness: A systematic review and meta‐analysis of randomized controlled trials
  Rishi Jobanputra, Jack A. Sargeant, Abdullah Almaqhawi, Ehtasham Ahmad, Franciskos Arsenyadis, David R. Webb, Louisa Y. Herring, Kamlesh Khunti, Melanie J. Davies, Thomas Yates
  Obesity Reviews.2023;[Epub]     CrossRef
• Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial
  Rasmus M. Sandsdal, Christian R. Juhl, Simon B. K. Jensen, Julie R. Lundgren, Charlotte Janus, Martin B. Blond, Mads Rosenkilde, Adrian F. Bogh, Lasse Gliemann, Jens-Erik B. Jensen, Charalambos Antoniades, Bente M. Stallknecht, Jens J. Holst, Sten Madsbad
  Cardiovascular Diabetology.2023;[Epub]     CrossRef
• Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis
  Sabine Kahl, Jennifer Pützer, Michael Roden
  Seminars in Liver Disease.2022; 42(01): 048.     CrossRef
• Effect of Empagliflozin Versus Placebo on Body Fluid Balance in Patients With Acute Myocardial Infarction and Type 2 Diabetes Mellitus: Subgroup Analysis of the EMBODY Trial
  Yu Hoshika, Yoshiaki Kubota, Kosuke Mozawa, Shuhei Tara, Yukichi Tokita, Kenji Yodogawa, Yu-Ki Iwasaki, Takeshi Yamamoto, Hitoshi Takano, Yayoi Tsukada, Kuniya Asai, Masaaki Miyamoto, Yasushi Miyauchi, Eitaro Kodani, Mitsunori Maruyama, Jun Tanabe, Wataru
  Journal of Cardiac Failure.2022; 28(1): 56.     CrossRef
• Effect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats
  Shohei Yamada, Yuji Ogura, Kazuho Inoue, Jun Tanabe, Takeshi Sugaya, Keiichi Ohata, Yoshio Nagai, Yasunori Natsuki, Seiko Hoshino, Shiika Watanabe, Daisuke Ichikawa, Kenjiro Kimura, Yugo Shibagaki, Atsuko Kamijo-Ikemori
  Molecular and Cellular Endocrinology.2022; 539: 111472.     CrossRef
• Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt/-catenin signaling pathway
  Olfa Khalifa, Neyla S. AL-Akl, Khaoula Errafii, Abdelilah Arredouani
  Scientific Reports.2022;[Epub]     CrossRef
• Body composition changes at 12 months following different surgical weight loss interventions in adults with obesity: A systematic review and meta‐analysis of randomized control trials
  Amy Sylivris, Jakub Mesinovic, David Scott, Paul Jansons
  Obesity Reviews.2022;[Epub]     CrossRef
• Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study
  Kohei Kaku, Kazuhiro Yamamoto, Yumiko Fukushima, Hristo Lliev, Atsutaka Yasui
  Expert Opinion on Drug Safety.2022; 21(10): 1315.     CrossRef
• Safety and effectiveness of empagliflozin according to body mass index in Japanese patients with type 2 diabetes: a subgroup analysis of a 3-year post-marketing surveillance study
  Kohei Kaku, Kazuhiro Yamamoto, Yumiko Fukushima, Seiko Mizuno, Daisuke Nitta
  Expert Opinion on Drug Safety.2022; 21(11): 1411.     CrossRef
• Le risque de dénutrition chez le sujet âgé diabétique : une limite à l’utilisation des « nouvelles » classes thérapeutiques ?
  Lyse Bordier, Jean Doucet, Bernard Bauduceau
  Médecine des Maladies Métaboliques.2022; 16(5): 422.     CrossRef
• Emerging evidence of the relationship between fat-free mass and ghrelin, glucagon-like peptide-1, and peptide-YY
  Austin J. Graybeal, Jada L. Willis, Elisa Morales-Marroquin, Grant M. Tinsley, Sarah E. Messiah, Meena Shah
  Nutrition.2022; 103-104: 111815.     CrossRef
• The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study
  Yoshinori Ozeki, Takayuki Masaki, Akari Kamata, Shotaro Miyamoto, Yuichi Yoshida, Mitsuhiro Okamoto, Koro Gotoh, Hirotaka Shibata
  Medicines.2022; 9(9): 47.     CrossRef
• Distribution of lean mass and mortality risk in patients with type 2 diabetes
  Li Ding, Yuxin Fan, Jingting Qiao, Jing He, Ruodan Wang, Qing He, Jingqiu Cui, Zhongshu Ma, Fangqiu Zheng, Hua Gao, Chenlin Dai, Hongyan Wei, Jun Li, Yuming Cao, Gang Hu, Ming Liu
  Primary Care Diabetes.2022; 16(6): 824.     CrossRef
• Cardio-sarcopenia: A syndrome of concern in aging
  De Rong Loh, Ru-San Tan, Wee Shiong Lim, Angela S. Koh
  Frontiers in Medicine.2022;[Epub]     CrossRef
• Type 2 diabetes
  Ehtasham Ahmad, Soo Lim, Roberta Lamptey, David R Webb, Melanie J Davies
  The Lancet.2022; 400(10365): 1803.     CrossRef
• Elevated circulating level of β-aminoisobutyric acid (BAIBA) in heart failure patients with type 2 diabetes receiving sodium-glucose cotransporter 2 inhibitors
  Satoshi Katano, Toshiyuki Yano, Hidemichi Kouzu, Ryohei Nagaoka, Ryo Numazawa, Kotaro Yamano, Yusuke Fujisawa, Katsuhiko Ohori, Nobutaka Nagano, Takefumi Fujito, Ryo Nishikawa, Wataru Ohwada, Masaki Katayose, Tatsuya Sato, Atsushi Kuno, Masato Furuhashi
  Cardiovascular Diabetology.2022;[Epub]     CrossRef
• An overview of anamorelin as a treatment option for cancer-associated anorexia and cachexia
  Guilherme Wesley Peixoto Da Fonseca, Stephan von Haehling
  Expert Opinion on Pharmacotherapy.2021; 22(7): 889.     CrossRef
• Liraglutide Does Not Adversely Impact Fat‐Free Mass Loss
  Andrew Grannell, William P. Martin, Babak Dehestani, Werd Al‐Najim, John C. Murphy, Carel W. Roux
  Obesity.2021; 29(3): 529.     CrossRef
• Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium–glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabet
  Daisuke Yabe, Kosuke Shiki, Keiko Suzaki, Thomas Meinicke, Yutaro Kotobuki, Kenichiro Nishida, Douglas Clark, Atsutaka Yasui, Yutaka Seino
  BMJ Open.2021; 11(4): e045844.     CrossRef
• Cancer Risk in Normal Weight Individuals with Metabolic Obesity: A Narrative Review
  Bethina Liu, Hugh E. Giffney, Rhonda S. Arthur, Thomas E. Rohan, Andrew J. Dannenberg
  Cancer Prevention Research.2021; 14(5): 509.     CrossRef
• Comprehensive analysis of LncRNAs expression profiles in an in vitro model of steatosis treated with Exendin-4
  Khaoula Errafii, Neyla S. Al-Akl, Olfa Khalifa, Abdelilah Arredouani
  Journal of Translational Medicine.2021;[Epub]     CrossRef
• Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus
  Vaneza Lira W. Wolf, Ikaro Breder, Luiz Sérgio F. de Carvalho, Alexandre A. S. Soares, Riobaldo M. Cintra, Joaquim Barreto, Daniel B. Munhoz, Sheila T. Kimura-Medorima, Wilson Nadruz, Gil Guerra-Júnior, Thiago Quinaglia, Elza Muscelli, Andrei C. Sposito
  Nutrition & Diabetes.2021;[Epub]     CrossRef
• Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors
  Marc Evans, Angharad R. Morgan, Zaheer Yousef, Gethin Ellis, Umesh Dashora, Dipesh C. Patel, Pam Brown, Wasim Hanif, Johnathan N. Townend, Naresh Kanumilli, Jim Moore, John P. H. Wilding, Stephen C. Bain
  Drugs.2021; 81(11): 1243.     CrossRef
• Glucose-lowering Drugs and Hospitalization for Heart Failure: A Systematic Review and Additive-effects Network Meta-analysis With More Than 500 000 Patient-years
  Riobaldo M Cintra, Ana Claudia Nogueira, Isabella Bonilha, Beatriz M Luchiari, Otavio R Coelho-Filho, Otavio R Coelho, Pedro Schwartzmann, Elza Muscellie, Wilson Nadruz, Luiz Sergio F Carvalho, Andrei C Sposito
  The Journal of Clinical Endocrinology & Metabolism.2021; 106(10): 3060.     CrossRef
• Physical activity and exercise in the management of type 2 diabetes: where to start?
  Deirdre Harrington, Joe Henson
  Practical Diabetes.2021; 38(5): 35.     CrossRef
• Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes
  
  New England Journal of Medicine.2021; 385(22): 2105.     CrossRef
• Effects of Antidiabetic Drugs on Muscle Mass in Type 2 Diabetes Mellitus
  Satoshi Ida, Ryutaro Kaneko, Kanako Imataka, Kaoru Okubo, Yoshitaka Shirakura, Kentaro Azuma, Ryoko Fujiwara, Kazuya Murata
  Current Diabetes Reviews.2021; 17(3): 293.     CrossRef
• Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: A randomized controlled study
  Hirotatsu Nakaguchi, Yoshinobu Kondo, Mayu Kyohara, Hiromi Konishi, Koji Oiwa, Yasuo Terauchi
  Journal of Diabetes Investigation.2020; 11(6): 1542.     CrossRef
• Sodium Glucose Co-Transporter 2 Inhibition Does Not Favorably Modify the Physiological Responses to Dietary Counselling in Diabetes-Free, Sedentary Overweight and Obese Adult Humans
  Shane P.P. Ryan, Alissa A. Newman, Jessie R. Wilburn, Lauren D. Rhoades, S. Raj J. Trikha, Ellen C. Godwin, Hayden M. Schoenberg, Micah L. Battson, Taylor R. Ewell, Gary J. Luckasen, Laurie M. Biela, Christopher L. Melby, Christopher Bell
  Nutrients.2020; 12(2): 510.     CrossRef
• GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report
  Eva W. Iepsen, Christian T. Have, Simon Veedfald, Sten Madsbad, Jens J. Holst, Niels Grarup, Oluf Pedersen, Ivan Brandslund, Jens-Christian Holm, Torben Hansen, Signe S. Torekov
  Cell Reports Medicine.2020; 1(1): 100006.     CrossRef
• Glucagon‐like peptide 1 infusions overcome anabolic resistance to feeding in older human muscle
  Haitham Abdulla, Bethan E. Phillips, Daniel J. Wilkinson, Marie Limb, Tereza Jandova, Joseph J. Bass, Debbie Rankin, Jessica Cegielski, Mariwan Sayda, Hannah Crossland, John P. Williams, Kenneth Smith, Iskandar Idris, Philip J. Atherton
  Aging Cell.2020;[Epub]     CrossRef